Targeted and long-lasting formulations of chemotherapeutics with low doses and few side effects. Simple formulations to delivery two or more therapeutics to cancers with similar pharmacokinetic profiles. Easier to manufacture than nano / micro particles. Good to use in combination with immune checkpoint inhibitors. Clinical Applications To sensitize the responses of cancers to chemotherapeutics. rHSA-p53 […]
Oncology
Braftide is a synthetic peptide inhibitor that works via a novel dual mechanism of action to inhibit BRAF, a protein that is responsible for cell proliferation, differentiation, and migration. This protein is an integral part of the MAP kinase / ERK signaling pathway. Mutations in BRAF have been identified in melanoma, colorectal cancer, non-Hodgkins lymphoma, […]
The University of the Sciences research team has uncovered CAPER as a novel therapeutic target inside breast cancer cells. CAPER has been shown to be overexpressed in these cancer cells and seems to be helping the cancer thrive and survive. Targeted cancer therapy is becoming a leading approach to cancer treatment and Dr. Jasmin and […]
The Glucagon-Like Peptide 1 Receptor (GLP-1R), a member of Class B family of G-protein coupled receptors (GPCRs), is an effective target for the treatment of type-2 diabetes, and its incretin peptide and varied peptide mimetics are adopted drugs. Despite remarkable anti-diabetic effects, GLP-1R peptide-based agonists are limited by several disadvantages. Although considerable progress has been […]
Lead Inventor Clyde M. Ofner III, Ph.D Unmet Need A major challenge in cancer chemotherapy is the selective delivery of small molecule anti-cancer agents to cancer cells. Doxorubicin (DOX) is a potent antineoplastic agent that is effective against a wide range of solid tumors and lymphomas but it is also associated with an irreversible cardiomyopathy […]